The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Open accessAbstract
BACKGROUND: In Parkinson disease (PD), the benefit of levodopa therapy becomes less marked over time, perhaps because degeneration of nigrostrial neurons causes progressive loss of aromatic l-amino acid decarboxylase (AADC), the enzyme that converts levodopa into dopamine. In a primate model of PD, intrastriatal infusion of an adeno-associated viral type 2 vector containing the human AADC gene (AAV-hAADC) results in robust response to low-dose levodopa without the side effects associated with higher doses. These data prompted a clinical trial. METHODS: Patients with moderately advanced PD received bilateral intraputaminal infusion of AAV-hAADC vector. Low-dose and high-dose cohorts (5 patients in each) were studied using standardized clinical rating scales at baseline and 6 months. PET scans using the AADC tracer [(18)F]fluoro-L-m-tyrosine (FMT) were performed as a measure of gene expression. RESULTS: The gene therapy was well tolerated, but 1 symptomatic and 2 asymptomatic intracranial hemorrhages followed the operative procedure. Total and motor rating scales improved in both cohorts. Motor diaries also showed increased on-time and reduced off-time without increased "on" time dyskinesia. At 6 months, FMT PET showed a 30% increase of putaminal uptake in the low-dose cohort and a 75% increase in the high-dose cohort. CONCLUSION: This study provides class IV evidence that bilateral intrastriatal infusion of adeno-associated viral type 2 vector containing the human AADC gene improves mean scores on the Unified Parkinson's Disease Rating Scale by approximately 30% in the on and off states, but the surgical procedure may be associated with an increased risk of intracranial hemorrhage and self-limited headache.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subsequent dose-escalation study demonstrated similar results with a 30% increase in AADC expression on positron emission tomography (PET) scan in the low-dose cohort and 75% increase in the high-dose cohort.51”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [51]
In the citing paper
“In this study, three patients had a postoperative intracranial hemorrhage (one symptomatic, two asymptomatic).51”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [51]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Self-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500
Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406
Self-citationResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
Self-citationHauser, R. A., Friedlander, J., Zesiewicz, T. A., Adler, C. H., Seeberger, L. C., O'Brien, C. F., Molho, E. S., & Factor, S. A. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200003000-00003 · Cited by 300
Cited by
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Institutional and/or industry partners FDA breakthrough/EMA* PRIME designation or product approval CNS Parkinson’s disease AAV2-AADC (101, 102) Jichi Medical University/ UCSF/Voyager .. ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... ..…”
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“Delivery of small amounts of AAV vectors directly into the brain has been tested in a number of trials for Parkinson disease, 13,51,52,107 Canavan disease, 14,108 and late infantile neuronal ceroid lipofuscinosis.”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Metadata
- Authors
- Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Aminoff, M. J.
- ORCID
- Venue
- Neurology
- Published
- 2009-11-17
- Volume
- 73
- Issue
- 20
- Pages
- 1662-1669
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2839805
- OpenAlex
- W2141355937
- Cited by
- 445
- References
- 20
- Citations by year
- 2026: 18 · 2025: 25 · 2024: 31 · 2023: 16 · 2022: 19 · 2021: 24 · 2020: 21 · 2019: 25 · 2018: 27 · 2017: 23 · 2016: 18 · 2015: 26 · 2014: 25 · 2013: 35 · 2012: 35
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- U.S. Department of Energy (FG02-08ER64699)
- Lupus Research Alliance
- Eisai
- National Institutes of Health (1s10rr023051-01)
- University of California, San Francisco
- Avid Radiopharmaceuticals
- National Institute on Aging (AG027984, R01AG027984, R41AG030241, AG 024904, R01AG027859, AG027859)
- National Cancer Institute (R01 CA94253-01, R01CA135358, R01CA119414, R01CA135626, U54 CA 90788, R01CA094253, U54CA090788)
- National Institute of Neurological Disorders and Stroke (R01NS037167, R01 NS-37167, R01NS046487, U10NS044460)
- National Institute of Biomedical Imaging and Bioengineering (R01EB000482)
- National Center for Research Resources (S10 RR023051)
- Lawrence Berkeley National Laboratory
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, aromatic L-amino acid decarboxylase, levodopa, intracranial hemorrhage, safety and tolerability, gene expression, motor symptoms, levodopa-induced dyskinesia
- MeSH terms
- Aged, Aromatic-L-Amino-Acid Decarboxylases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease, Putamen, Severity of Illness Index, Time Factors, Genetic Therapy, Cohort Studies, Treatment Outcome, Neurosurgical Procedures, Intracranial Hemorrhages, Dyskinesias, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181c29356
- The paper
- Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0b013e3181c29356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.